There are currently 552 clinical trials in Charlotte, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Carolinas Medical Center, Carolinas Medical Center/Levine Cancer Institute, Novant Health Presbyterain Medical Center and Levine Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Carolinas Medical Center, Levine Children's Hospital, Charlotte, North Carolina
Conditions: Langerhans Cell Histiocytosis
Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System
Recruiting
This is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3 LVAS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2023
Locations: Atrium Health Sanger Heart and Vascular Institute, Charlotte, North Carolina
Conditions: Heart Failure
Effects of Early Weight Bearing on Rehabilitation Outcomes in Patients With Traumatic Ankle and Tibial Plateau Fractures
Recruiting
The overall objective of this study is to compare outcomes following early versus delayed weight bearing for adult patients operatively treated for an ankle fracture without syndesmotic fixation. Additionally, early weight bearing will be tested in patients with unicondylar plateau fractures that do not involve joint impaction in the context of a pilot study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2023
Locations: Carolinas Medical Center, Charlotte, North Carolina
Conditions: Rehabilitation
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Recruiting
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2023
Locations: Carolinas Medical Center, Charlotte, North Carolina
Conditions: Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Randomized Therapy In Status Epilepticus
Recruiting
This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/22/2023
Locations: Marinus Research Site, Charlotte, North Carolina
Conditions: Status Epilepticus
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Recruiting
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
Gender:
All
Ages:
1 year and above
Trial Updated:
02/15/2023
Locations: Carolinas Medical Center/Levine Children's Hospital (Atrium Health), Charlotte, North Carolina
Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
Recruiting
The purpose of this study is to evaluate the device performance and monitor the safety and effectiveness of the Berlin Heart EXCOR Active Driving System while being used with the approved EXCOR Pediatric Ventricular Assist Device. EXCOR Active Driving System is intended for use with the approved EXCOR Pediatric VAD. The EXCOR Pediatric VAD is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric candidates with severe isolat... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
02/06/2023
Locations: Levine Children's Hospital, Charlotte, North Carolina
Conditions: Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Levine Children's Specialty Center, Charlotte, North Carolina +2 locations
Conditions: Venous Thromboembolism
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Colorectal Cancer
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Novant Health Cancer Institute - Elizabeth (Hematology), Charlotte, North Carolina
Conditions: Leukemia, Myeloid, Acute
Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes
Recruiting
The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 25 centers in the Unite... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2022
Locations: Carolinas Research Institute - Mallard Creek, Charlotte, North Carolina
Conditions: Chronic Pain